Menu Search
Equities

Faes Farma SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FFEA:MUN

Faes Farma SA

Actions
  • Price (EUR)5.32
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+47.78%
  • Beta0.3346
Data delayed at least 15 minutes, as of Feb 16 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

  • Revenue in EUR (TTM)568.11m
  • Net income in EUR105.08m
  • Incorporated1933
  • Employees756.00
  • Location
    Faes Farma SAAvda. Autonomia 10LEIOA 48940SpainESP
  • Phone+34 944818300
  • Fax+34 944818301
  • Websitehttps://faesfarma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		FAE:MCE since
announced		Transaction
value
SIFI SpADeal completed29 May 202529 May 2025Deal completed20.42%366.01m
Laboratorio Edol Produtos Farmaceuticos SaDeal completed25 Mar 202525 Mar 2025Deal completed47.44%81.00m
Data delayed at least 15 minutes, as of Feb 16 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.